We thank Dr Brion and colleagues[@bib1] for their interest in our early review and appraisal of the risk of vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The circulation of medical information has probably never been so fluid and volatile than during this unfortunately still evolving pandemic. This gives additional value to such correspondence letters and opportunities for useful updates. Indeed, as this valid adjunct was submitted, a convincing case was made for a vertical, transplacental, hematogenous transmission to be plausible with SARS-CoV-2.[@bib2] In 1 case of maternal infection, a pregnant patient with symptoms of coronavirus disease 2019 at 35 weeks' gestation gave birth by cesarean delivery because of suspicious fetal heart rate and because concordant samples of cord blood, amniotic fluid, neonatal peripheral sites, and placental and vaginal secretions tested positive for SARS-CoV-2 by real time polymerase chain reaction test. The neonate had an uneventful recovery and a normal follow-up but had transient hypertonia and magnetic resonance imaging findings suggestive of inflammatory ischemic insult to the brain. The virus was not present in the cerebrospinal fluid, which only showed markers of inflammation. This finding is compatible with the hypothesis we raised that if the virus was unlikely to cross the placenta early in gestation, when the risk is that of malformative embryopathy, brain ischemia could occur in advanced pregnancy with a strongly positive viremia; in addition, maternal deregulated inflammation and/or hypoxemia could favor the development of related insults to the fetal organs, particularly the brain. Such cases should be subjected to long-term follow-up.[@bib3]
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